Sero Conversion of Viral Hepatitis among End Stage Renal Disease Patients on Hemodialysis in Kashmir: Results of a Prospective Study
DOI:
https://doi.org/10.3889/oamjms.2019.160Keywords:
Hepatitis C, Hepatitis B Hemodialysis units, Risk Factors, Seroepidemiologic studiesAbstract
BACKGROUND: The seroconversion is a significant health concern in patients with end-stage renal disease undergoing hemodialysis particularly in high endemic zones of HBV and HCV.
PATIENTS AND METHODS: This prospective study was conducted from January 2009 to April 2018 at Sheri Kashmir Institute of Medical Sciences, Srinagar, Kashmir. A cohort of 459 end-stage renal disease patients on hemodialysis was enrolled from four dialysis centres and followed in a longitudinal manner. Their seroconversion rates, risk factors were studied. Positive patients were treated and followed up.
RESULTS: This study demonstrated HBV seroconversion rate of 7.4 % (n = 34) and HCV seroconversion rate of 10% (n = 46) in a cohort of 459 patients on hemodialysis attending four dialysis centres of Kashmir. Patients with diabetes mellitus outnumbered in seroconversion rates of (43.75%) followed by patients with glomerulonephritis (23.75%). Of 15 patients who had undergone renal transplantation 10 (66.67%), patients had seroconversion on hemodialysis which was statistically significant (P < 0.001). Patients who were dialysed at multiple HD centres had significant seroconversion than those who followed up at a single center. Seroconversion was associated with longer duration of dialysis (80.30 ± 30.92 vs 61 ± 9.41months, P < 0.000). HBV vaccination of the ESRD patient on hemodialysis was significantly protective against seroconversion (P = 0.000).
CONCLUSIONS: Hepatitis B vaccination, stringent precautions in all dialysis centres could help to reduce the high seroconversion rates which have a high financial burden on ESRD patients. Intense health education to both patients and medical staff will be beneficial to lower the seroconversion rates.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Kurz P, Köhler H, Meuer S, Hütteroth T, Meyer zum Büschenfelde KH. Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int. 1986; 29(6):1209-14. https://doi.org/10.1038/ki.1986.129 PMid:3489122
Moloughney BW. Transmission and postexposure management of bloodborne virus infections in the health care setting: Where are we now? CMAJ. 2001; 165:445-51. PMid:11531058 PMCid:PMC81374
Akpolat T, Dilek M, Yavuz M, Utas C et al Turkish Multicenter PD Study Group. Low seroconversion rates in CAPD patients compared to hemodialysis patients: potential advantages for transplant candidates. Perit Dial Int. 2002; 22(4):520-3. PMid:12322827
Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012; 19(9):601-7. https://doi.org/10.1111/j.1365-2893.2012.01633.x PMid:22863263
Myers RP, Krajden M, Bilodeau M, et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014; 28:243–50. https://doi.org/10.1155/2014/317623 PMid:24839620 PMCid:PMC4049256
Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int. 2003; 63:2222-9. https://doi.org/10.1046/j.1523-1755.2003.00017.x PMid:12753311
Almawi WY, Qadi AA, Tamim H, Ameen G, Bu-Ali A, Arrayid S, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among dialysis patients in Bahrain and Saudi Arabia, Transplant Proc. 2004; 36:1824-6. https://doi.org/10.1016/j.transproceed.2004.07.019 PMid:15350487
Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail. 2006; 28:729-35. https://doi.org/10.1080/08860220600925602 PMid:17162434
Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, et al. Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: Prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz. 2006; 101:689-92. https://doi.org/10.1590/S0074-02762006000600019 PMid:17072485
Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: Analysis of registry data. Nephrol Dial Transplant. 2009; 24:1598-603. https://doi.org/10.1093/ndt/gfn684 PMid:19096083
Malhotra R, Soin D, Grover P, Galhotra S, Khutan H, Kaur N. Hepatitis B virus and hepatitis C virus co-infection in hemodialysis patients: A retrospective study from a tertiary care hospital of North India. J Nat Sci Biol Med. 2016; 7(1):72-4. https://doi.org/10.4103/0976-9668.175076 PMid:27003974 PMCid:PMC4780172
Wreghitt TG. Blood-borne virus infections in dialysis units — A review. Rev Med Virol. 1999; 9:101-9. https://doi.org/10.1002/(SICI)1099-1654(199904/06)9:2<101::AID-RMV234>3.0.CO;2-U
Souqiyyeh MZ, Al-Attar MB, Zakaria H, Shaheen FA. Dialysis centers in the kingdom of saudi arabia. Saudi J Kidney Dis Transpl. 2001; 12(3):293–304. PMid:18209376
Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE: Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut. 2002, 51(3):429–433. https://doi.org/10.1136/gut.51.3.429
Buturović-Ponikvar J. Renal replacement therapy in Slovenia: annual report 2001. Nephrology Dialysis Transplantation. 2003; 18(Suppl 5):v53-5. https://doi.org/10.1093/ndt/gfg1048 PMid:12817072
Boulaajaj K, Elomari Y, Elmaliki B, Madkouri B, Zaid D, Benchemsi N. Prevalence of hepatitis C, hepatitis B and HIV infection among haemodialysis patients in Ibn-rochd university hospital, casablanca. Nephrol Ther. 2005; 1(5):274–284. https://doi.org/10.1016/j.nephro.2005.06.012 PMid:16895696
Zahran AM. Prevalence of seroconversion of hepatitis C virus among hemodialysis patients in Menoufia Governorate, Egypt. Arab J Nephrol Transplant. 2014; 7(2):133-5. PMid:25366511
Saxena AK, Panhotra BR. The susceptibility of patients with type-2 diabetes to hepatitis C virus infection during long-term haemodialysis. Swiss Med Wkly. 2003; 133:611-8. PMid:14745667
Ocak S, Duran N, Kaya H, Emir I. Seroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysis. Int J Clin Pract. 2006; 60:670-4. https://doi.org/10.1111/j.1368-5031.2006.00738.x PMid:16805751
Carneiro MA, Martins RM, Teles SA, Silva SA, Lopes CL, Cardoso DD, et al. Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: A survey by polymerase chain reaction and serological methods. Mem Inst Oswaldo Cruz. 2001; 96:765-9. https://doi.org/10.1590/S0074-02762001000600003 PMid:11562698
Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001; 37:1004-10. https://doi.org/10.1016/S0272-6386(05)80017-4
Wong PN, Fung TT, Mak SK, Lo KY, Tong GM, Wong Y, et al. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol. 2005; 20:1641-51. https://doi.org/10.1111/j.1440-1746.2005.03837.x PMid:16246180
Afzali A, Weiss NS, Boyko EJ, Ioannou GN. Association between serum uric acid level and chronic liver disease in the United States. Hepatology. 2010; 52(2):578-89. https://doi.org/10.1002/hep.23717 PMid:20683957
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2008; 109(Suppl):S1-99.
Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR. 2001; 50:1-43.
de Oliveira Júnior WV, Sabino Ade P, Figueiredo RC, Rios DR. Inflammation and poor response to treatment with erythropoietin in chronic kidney disease. J Bras Nefrol. 2015; 37(2):255-63. https://doi.org/10.5935/0101-2800.20150039 PMid:26154647
Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005; 18:52-61. https://doi.org/10.1111/j.1525-139X.2005.18108.x PMid:15663766
Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, et al. Occult hepatitis B virus infection in dialysis patients: A multicentre survey. Aliment Pharmacol Ther. 2005; 21:1341-7. https://doi.org/10.1111/j.1365-2036.2005.02501.x PMid:15932364
Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004; 40:1072-7. https://doi.org/10.1002/hep.20435 PMid:15486926
Centers for Disease Control. Hepatitis: control measures for hepatitis B in dialysis centers. HEW publication no. (CDC). 1977; 78-8358.
Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am J Kidney Dis. 2005; 46:997-1011. https://doi.org/10.1053/j.ajkd.2005.08.032 PMid:16310566
Gutiérrez-GarcÃa ML, Fernandez-Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. World J Gastroenterol. 2011; 17:1538-42. https://doi.org/10.3748/wjg.v17.i12.1538 PMid:21472117 PMCid:PMC3070122
Somi MH, Etemadi J, Ghojazadeh M, et al Risk factors of HCV seroconversion in hemodialysis patients in tabriz, iran. Hepat Mon. 2014; 14(6):e17417. https://doi.org/10.5812/hepatmon.17417
Jasuja S, Gupta AK, Choudhry R, Kher V, et al Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital. Indian J Nephrol. 2009; 19(2):62-7. https://doi.org/10.4103/0971-4065.53324 PMid:20368926 PMCid:PMC2847810
Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol. 2003; 36:47-53. https://doi.org/10.1097/00004836-200301000-00015 PMid:12488709
Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39:1147-71. https://doi.org/10.1002/hep.20119 PMid:15057920
Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, et al. Occult hepatitis B virus infection in dialysis patients: A multicentre survey. Aliment Pharmacol Ther. 2005; 21:1341-7. https://doi.org/10.1111/j.1365-2036.2005.02501.x PMid:15932364
Abdelmoemen G, Khodeir SA, Abou-Saif S, Kobtan A, Abd-Elsalam S. Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta university hospitals: a single-center study. Environ Sci Pollut Res Int. 2018; 25(6):5459-5464. https://doi.org/10.1007/s11356-017-0897-y PMid:29214477
Cheng SB, Wu CC, Shu KH, Ho WL, Chen JT, Yeh DC, Liu TJ, P'eng FK. Liver resection for hepatocellular carcinoma in patients with end-stage renal failure. J Surg Oncol. 2001; 78(4):241-6. https://doi.org/10.1002/jso.1160 PMid:11745817
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Ibrahim Masoodi, Charanjit Singh, Imtiyaz Ahmad Wani, Muzafar Maqsood Wani, Tousief Irshad Ahmed, Rayeеs Yousuf Sheikh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
